Le notizie dalla Borsa Italiana del overland-adct-biopharma-announces-nmpa-accepts-biologics-license-application-and-grants-priority-review-for-zynlonta-for-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-1503218


Condividi